摘要
目的比较瑞舒伐他汀与辛伐他汀对冠心病患者血脂及炎症反应的控制强度及安全性。方法 2013年4月~2014年4月期间收集德胜中心综合病房治疗和门诊随访的冠心病合并高脂血症的患者236例,其中男性144例,女性92例,年龄57~81岁,平均年龄(62.4±12.7)岁。随机分为实验组和对照组,两组均为118例。在常规治疗基础上,实验组给予瑞舒伐他汀,对照组给予辛伐他汀,治疗12周。检测治疗前后两组患者低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、总胆固醇(TC)、载脂蛋白A1(Apo A1)、载脂蛋白B(Apo B)、超敏C反应蛋白(hsCRP)、血尿素氮(BUN)、血肌酐(Cr)、丙氨酸氨基转移酶(ALT)、肌酸激酶(CK)等指标。记录心血管事件。结果两组患者在性别、年龄及其它合并症(包括高血压、糖尿病)等方面比较,差异均无统计学意义(P均〉0.05)。治疗前,两组患者各项血脂指标比较,差异无统计学意义(P均〉0.05)。治疗后,两组患者各项血脂指标均有明显改善,差异有统计学意义(P均〈0.05)。与对照组治疗后比较,实验组LDL-C、TG、TC等下降,HDL-C升高,差异具有统计学意义(P均〈0.05)。实验组治疗后hs-CRP、Apo A1、Apo B等指标水平明显低于对照组,差异具有统计学意义(P均〈0.05)。经12周治疗后,两组有部分患者Cr、BUN指标稍有升高,但与治疗前比较差异无统计学意义(P均〉0.05)。两组患者在治疗、随访期间无一例发生心血管事件。结论瑞舒伐他汀降低血脂及减轻炎症反应效果明显优于辛伐他汀,且安全性良好。
Objective To compare the effects between Rosuvastatin and simvastatin on blood lipid and high sensitive C reactive protein(hs-CRP) among patients with coronary heart disease(CHD). Methods 236 patients(male/female=144/92, age=57~81, average age=62.4±12.7) with CHD and hyperlipoidemia were collected from 2013.04~2014.04 from Deshengmen Community Health Centre of Xicheng District of Beijing, and divided into rosuvastatin group(observation group) and simvastatin group(control group). The low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), triglyceride(TG), total cholesterol(TC), apolipoprotein A1(Apo A1), apolipoprotein B(Apo B), high-sensitivity C-reactive protein(hs-CRP), blood urea nitrogen(BUN), serum creatinine(Cr), alanine aminotransferase(ALT), creatine kinase(CK) of the two groups were observed. Results No significant differences(P〉0. 05) were observed in sex, age, complications(including high blood pressure, diabetes), and indexes of blood lipid. Compared to control group, TG, TC, LDL-C, hs-CRP, Apo A1, Apo B were decreased, and HDL-C was increased significantly in observation group after treatment(P〈0. 05). No significant differences were Cr and BUN in observation group and control group after 12 weeks' treatment(P〉0. 05). And none cardiovascular eventwas observed during treatment and follow-up. Conclusion Rosuvastatin is more effectively and safer reducing blood lipids and hs-CRP than simvastatin.
出处
《中国循证心血管医学杂志》
2016年第2期206-209,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine